{'fraction_non_alphanumeric': 0.01229895931882687, 'fraction_numerical': 0.0, 'mean_word_length': 5.87012987012987, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Immunotherapy in lymphoma

A multitude of studies have investigated why the immune system fails to develop an effective response against cancer and how to mobilize a successful immune therapeutic attack against cancer cells. Lymphomas are tumours of the immune system that develop from the cells devoted to the body defence within permissive specialized and well‐ vascularized tissue microenvironments, such as bone marrow and secondary lymphoid organs. Malignant lymphoid cells entail a bidirectional dialogue with a host of nonmalignant immune cells of both innate and adaptive immunity. This cross‐talk not only favours malignant cell growth, survival, and drug resistance but also prevents antitumour response through resistance to cytotoxicity, compromised cytotoxic cell activity, and altered tumour‐identifying ligand expression or secretion. Improving the understanding of the mechanisms that underlie the deficiency of an adequate antitumour immune response is now allowing manipulation of the immune system for the purpose of lymphoma eradication.